Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... (PRWEB) March 31, 2015 Diasome Pharmaceuticals, ... licensor, SDG, Inc., that a United States patent has ... insulin therapy. , Entitled “Lipid Construct for ... composition of matter claims related to the use of ... for enabling injected insulin to more effectively reach the ...
(Date:3/30/2015)... NC (PRWEB) March 30, 2015 ... are pleased to announce the formation of VaxCorps, ... research centers specializing in the conduct of vaccine ... VaxCorps clinical sites have successfully conducted over ... experience in seasonal and pandemic influenza as well ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... (CFDA) has approved the Company,s application to conduct a ... carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
Breaking Biology Technology:Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5
... , , For transfection of cells with siRNA in RNAi procedures, , , ... , , , , , ... Quick and easy setup , Ready-to-use reagent , ... , , , Principle , , , , ...
... , , , , ... Kppers, Gaby Schulte, Silke Zobel, and Dirk Lffert , ... Microsatellites highly polymorphic DNA markers comprised of nucleotides , ... the genome , are a useful tool for ...
... , , , Andreas Pahl, Uwe Oelmller,* ... Department of Pharmacology, University of Erlangen, Erlangen, Germany , , ... , , , Drug library screening based on ... purification , and sensitive, quantitative, real-time RT-PCR analysis. This article demonstrates ...
Cached Biology Technology:TransMessenger Transfection Reagent 2TransMessenger Transfection Reagent 3Fully automated DNA purification and efficient multiplex PCR for analysis , of microsatellite loci 2Fully automated DNA purification and efficient multiplex PCR for analysis , of microsatellite loci 3Fully automated DNA purification and efficient multiplex PCR for analysis , of microsatellite loci 4Fully automated DNA purification and efficient multiplex PCR for analysis , of microsatellite loci 5High-throughput gene expression analysis to screen for anti-asthma drugs 2High-throughput gene expression analysis to screen for anti-asthma drugs 3High-throughput gene expression analysis to screen for anti-asthma drugs 4
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
(Date:3/11/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) ... Market by Product, Application & By Geography - Global ... offering. , This report predicts that the ... by 2020, with an estimated CAGR of 10.6%. ... types such as contact cards & readers, contactless cards ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... successfully piloted a process that enables natural resource ... plants and ecosystems as climate changes. The ... practical approach to assessing how future changes in ... and other environmental conditions might affect natural resources. ...
... Societies for Experimental Biology (FASEB) is once again calling ... prevent sequestration, the automatic across-the-board budget cuts that are ... automatic spending cuts will stop science advances in their ... FASEB President, Judith S. Bond, PhD. , A ...
... MRI and Honorary Lecturer in Cardiovascular Medicine at The University ... the only location in the UK where the trial is ... test manufacturer, to take part in the trial as he ... heart attacks. The other trial sites are in Australia, ...
Cached Biology News:A game plan for climate change 2A game plan for climate change 3Manchester patients take part in pioneering heart attack blood test trial 2
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
PSMD1 Antibody...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Biology Products: